Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

Cel-Sci Corporation (CVM) Prices Public Offering, Stock Plummets

Equities.com April 14, 2014

CEL-SCI Corporation Prices $10 Million Public Offering of Common Stock and Six Month Warrants

Business Wire April 14, 2014

CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants

Business Wire April 11, 2014

Henry Ford Health System of Detroit to Enroll and Treat Patients in CEL-SCI's Phase III Head and Neck Cancer Clinical Trial

Business Wire April 8, 2014

CEL-SCI: Has A Notable Insider Buy and Multiple Catalysts Set The Table For A Major Short Squeeze?

Accesswire April 8, 2014

Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI's Global Phase III Head and Neck Cancer Trial

Business Wire April 2, 2014

CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial

Business Wire April 1, 2014

CEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear Channel Business Talk Radio

Marketwired March 25, 2014

CEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear Channel Business Talk Radio

Marketwired March 25, 2014

One Reason Why CEL-SCI Has Become One Of 2014's Top Percentage Gainers

Accesswire March 12, 2014

First U.S. Clinical Site Opens for CEL-SCI's Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion

Business Wire March 4, 2014

CEL-SCI Reports 146 Patients Enrolled in Its Phase III Immunotherapy Head and Neck Cancer Trial

Business Wire February 27, 2014

CEL-SCI Corporation Reports First Quarter 2014 Financial Results

Business Wire February 11, 2014

CEL-SCI to Present at 16th Annual BIO CEO & Investor Conference

Business Wire February 7, 2014

CEL-SCI Corporation Receives Approval for Listing and Trading of Warrants from the NYSE MKT under the Ticker Symbol "CVM WS"

Business Wire February 4, 2014

U.S. Navy Approves Start of CEL-SCI's Phase I Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

Business Wire February 3, 2014

Five Star Equities Issues New Research Reports on ARIA, CVM, NKTR and NTCT

Accesswire January 27, 2014

Surging MKT biotech companies sucked down with slumping market

Chris Parry January 24, 2014

CEL-SCI Receives Government Approval in Serbia to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

Business Wire January 23, 2014

CEL-SCI Reports Fiscal 2013 Financial Results and Clinical & Corporate Developments

Business Wire January 2, 2014